Company / Net Income
Amylyx Pharmaceuticals, Inc. Net Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$144.7M
FY2025
5-year range
-$301.7M / $49.3M
FY2021-FY2025
Trend
+52.0%
vs FY2024
Sector context
#128 of 216
Health Care
What the data says
At -$145M, Amylyx Pharmaceuticals, Inc.'s net income ranks #128 of 216 in the Health Care sector. Net Income has fluctuated over the past 5 years, ranging from -$302M in FY2024 to $49M in FY2023.
Based on SEC 10-K filings.
-$145M in FY2025.
Declined from $49M to -$145M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#128 of 216 in Health CareTop 59% of 216This company -$144.7M Sector average $454.3M
▼
-131.9% below sector average
Key checks
Key Insights
- In FY2025, net income increased 52.0% year-over-year.
- Ranks #128 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2023.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$144.7M | +52.0% |
| FY2024 | -$301.7M | -712.4% |
| FY2023 | $49.3M | +124.8% |
| FY2022 | -$198.4M | -125.6% |
| FY2021 | -$87.9M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026